Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type III alpha-1 chain (COL3A1)
- Target
- COL3A1
- Molecular classification
- Fibrillar collagen, Structural protein, Extracellular matrix protein
01
Overview
Collagen type III alpha-1 chain (COL3A1) is the main constituent of type III collagen, a homotrimeric fibrillar protein essential to the structure and function of connective tissues such as skin, blood vessels, and several internal organs. Synthesized as a procollagen molecule, it is processed to its mature triple-helical form and assembles into fibrils that co-localize with type I collagen, modulating tissue elasticity and tensile strength. It is crucial for wound healing and is involved in both normal tissue homeostasis and pathological fibrosis. Mutations in COL3A1 lead to vascular Ehlers-Danlos syndrome, characterized by fragile blood vessels and organs, while increased type III collagen is implicated in fibrotic disorders. Biomarkers derived from the propeptides of type III collagen synthesis are used in clinical practice to monitor fibrotic activity.
- Other names
- Type III collagenCollagen, type III, alpha-1Pro-α1(III)Reticulin (historic/structural context)
02
Mechanism of action
Inhibition of TGF-β pathway to reduce collagen production; Matrix metalloproteinase modulation to increase collagen degradation
03
Biological functions
Structural support in skin, blood vessels, lungs, and intestinesRegulation of collagen fibril diameter (especially co-assembly with type I collagen)Wound healingTissue repair and remodelingHemostasis via platelet aggregation
04
Disease associations
Ehlers-Danlos syndrome (vascular type)Fibrotic diseases (e.g., liver, kidney, systemic sclerosis)Cardiovascular disease (important in blood vessel integrity/rupture)Other connective tissue disorders
05
Safety considerations
Excess suppression may impair wound healing, vascular integrity, or tissue repairOverproduction is associated with fibrosis and tissue stiffeningGenetic defects (mutations) can result in vascular fragility, organ rupture
06
Interacting drugs
No direct drugs target COL3A1; however, agents that affect collagen synthesis such as antifibrotic drugs (pirfenidone, nintedanib), some TGF-β inhibitors, and general matrix metalloproteinase inhibitors can indirectly modulate type III collagen synthesis or degradation
07
Biomarkers
N-terminal propeptide of type III procollagen (PIIINP)C-terminal propeptide of type III procollagen (PIIICP)Circulating levels of these peptides are used to assess fibrosis and connective tissue turnover
Beyond the preview
Go deeper on Collagen type III alpha-1 chain (COL3A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Collagen type III alpha-1 chain (COL3A1).